Finally, IFN-β-treated monocytes and DCs of MS patients increased expression of PD-L1, a potent inhibitor of autologous CD4+ T cell activation contributing to the maintenance of peripheral tolerance [63]. The gene discussed is CD4; the disease is myeloid sarcoma.